New data shows TECVAYLI plus DARZALEX FASPRO significantly improves survival outcomes for patients with relapsed/refractory multiple myeloma, setting the stage for a new standard of care.
Johnson & Johnson announced strong third-quarter 2025 financial results, with reported sales increasing by 6.8% to $24.0 billion. The company’s Innovative Medicine and MedTech divisions both contributed to this growth. As a result of this strong performance, Johnson & Johnson has raised its full-year 2025 sales guidance.
Johnson & Johnson announces that the U.S. FDA has approved SIMPONI® (golimumab) for the treatment of moderately to severely active ulcerative colitis in children weighing at least 15 kg. This approval provides a new subcutaneous treatment option for younger UC patients.
The U.S. Food and Drug Administration (FDA) has given approval to TREMFYA® (guselkumab) for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in children. This groundbreaking approval makes TREMFYA® the first and only IL-23 inhibitor available for pediatric patients, offering a new ray of hope for thousands of children affected by these chronic conditions.
U.S. Food and Drug Administration (FDA) has officially approved INLEXZO™ (gemcitabine intravesical system), a novel drug-delivery system from Johnson & Johnson set to revolutionize care for adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). This first-of-its-kind therapy offers a significant bladder-sparing alternative for a high-risk patient group often facing complete bladder removal. Clinical trials showed an 82% complete response rate, marking a major advancement in bladder cancer treatment.
BARCELONA – According to an innovative study, patients with first-line EGFR-mutated non-small cell lung cancer (NSCLC) can avoid acquired resistance more effectively with a novel [Read More…]
New Brunswick, N.J. – Over the next ten years, Johnson & Johnson (JNJ) plans to invest a staggering $2 billion to build a state-of-the-art manufacturing [Read More…]
The U.S. FDA has declined to approve an expanded indication for Johnson & Johnson’s multiple myeloma therapy, Darzalex Faspro. The decision, delivered via a Complete Response Letter, was not based on the drug’s clinical efficacy but on unresolved issues at a third-party manufacturing facility.
Johnson & Johnson announced robust second-quarter 2025 financial results, surpassing analyst expectations and raising its full-year guidance. The healthcare giant reported a significant 5.8% increase in sales to $23.7 billion, driven by strong performances in its Innovative Medicine and MedTech segments.
Johnson & Johnson has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for the approval of STELARA® (ustekinumab) [Read More…]
